Boundless Bio (BOLD) Stock News, Mar-Apr 2024

BOLD Nasdaq

Welcome to our dedicated page for Boundless Bio news (Ticker: BOLD), a resource for investors and traders seeking the latest updates and insights on Boundless Bio stock.

Boundless Bio, Inc. develops clinical-stage oncology therapies aimed at oncogene-amplified tumors through extrachromosomal DNA (ecDNA) biology. Its news centers on BBI-940, an oral, selective Kinesin degrader and ecDNA-directed therapeutic candidate, including KOMODO-1 clinical development, preclinical AACR data, FDA IND acceptance, and cancer-model results.

Company updates also cover financial results, cash runway and capital allocation, conference appearances, and portfolio prioritization, including the discontinued POTENTIATE program that combined BBI-355, a CHK1 inhibitor, with BBI-825, an RNR inhibitor.

04/11/2024 08:00 AM

News

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.02%

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-5.75%

Boundless Bio Announces Pricing of Initial Public Offering

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-76.24%

FAQ

What is the current stock price of Boundless Bio (BOLD)?

The current stock price of Boundless Bio (BOLD) is $2.82 as of September 17, 2026.

What is the market cap of Boundless Bio (BOLD)?

The market cap of Boundless Bio (BOLD) is approximately 64.1M.